Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations

被引:12
|
作者
Qin, Qi [1 ,4 ]
Wei, Cuibai [1 ]
Piao, YueShan [2 ]
Lian, Fang [2 ]
Wu, Hao [3 ]
Zhou, Aihong [1 ]
Wang, Fen [1 ]
Zuo, Xiumei [1 ]
Han, Yue [1 ]
Lyu, Jihui [3 ]
Guo, Dongmei [1 ]
Jia, Jianping [1 ,5 ,6 ,7 ]
机构
[1] Capital Med Univ, Dept Neurol, Innovat Ctr Neurol Disorders, Xuanwu Hosp, 45 Changchun St, Beijing 100053, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Dept Pathol, Beijing, Peoples R China
[3] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China
[4] Beijing Geriatr Hosp, Ctr Cognit Disorders, Beijing, Peoples R China
[5] Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Beijing, Peoples R China
[6] Beijing Key Lab Geriatr Cognit Disorders, Beijing, Peoples R China
[7] Neurodegenerat Lab Minist Educ Peoples Republ, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
leptomeningeal amyloidosis; transthyretin; leptomeningeal enhancement; TTR mutations; FAMILIAL OCULOLEPTOMENINGEAL AMYLOIDOSIS; LIVER-TRANSPLANTATION; VARIANT; POLYNEUROPATHY; DIFLUNISAL; DIAGNOSIS; THERAPY; RARE; TAFAMIDIS; EFFICACY;
D O I
10.1097/NRL.0000000000000337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Leptomeningeal amyloidosis (LA) represents a rare subtype of familial transthyretin (TTR) amyloidosis, characterized by deposition of amyloid in cranial and spinal leptomeninges. Of >120 TTR mutations identified, few have been associated with LA. Case Report: A 27-year-old male presented with a 2-year history of progressive symptoms including cognitive decline and right-sided weakness and numbness. Cerebrospinal fluid (CSF) analyses demonstrated high protein level. Gadolinium-enhanced magnetic resonance imaging (MRI) revealed extensive leptomeningeal enhancement over the surface of the brain and spinal cord. Pathologic analyses revealed a TTR mutation c.113A>G (p.D38G). Review Summary: Fifteen mutations and genotype-phenotype correlation of 72 LA patients have been summarized to provide an overview of LA associated with transthyretin mutations. The mean age of clinical onset was 44.9 years and the neurological symptoms primarily included cognitive impairment, headache, ataxia seizures and hearing, visual loss. CSF analysis showed elevated high CSF protein level and MRI revealed extensive leptomeningeal enhancement. Conclusion: Clinicians should be aware of this rare form of familial transthyretin amyloidosis as well as its typical MRI enhancement and high CSF protein. The important role of biopsy, genetic testing and the potential early diagnosis value of contrast MRI were suggested. Early recognition of these characteristics is important to provide misdiagnosis and shorten the time before correct diagnosis. These findings expand the phenotypic spectrum of TTR gene and have implications for the diagnosis, treatment, and systematic study of LA.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 50 条
  • [21] The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis
    He, Shan
    He, Xinyue
    Liu, Lei
    Zhang, Wenbo
    Yu, Lanlan
    Deng, Zhun
    Feiyi Zhang
    Mo Shanshan
    Fan, Yue
    Zhao Xinyue
    Wang, Lun
    Wang Chenxuan
    Zhang Shuyang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [22] Tafamidis for the treatment of transthyretin amyloidosis
    Lorenzini, Massimiliano
    Elliott, Perry M.
    FUTURE CARDIOLOGY, 2019, 15 (02) : 53 - 61
  • [23] The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis
    Fan, Kuan
    Zhu, Haixia
    Xu, Hongbo
    Mao, Ping
    Yuan, Lamei
    Deng, Hao
    JOURNAL OF NEUROLOGY, 2019, 266 (01) : 232 - 241
  • [24] Hereditary transthyretin amyloidosis (ATTRv)
    Triposkiadis, Filippos
    Briasoulis, Alexandros
    Starling, Randall C.
    Magouliotis, Dimitrios E.
    Kourek, Christos
    Zakynthinos, George E.
    Iliodromitis, Efstathios K.
    Paraskevaidis, Ioannis
    Xanthopoulos, Andrew
    CURRENT PROBLEMS IN CARDIOLOGY, 2025, 50 (04)
  • [25] Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management
    Alcantara, Monica
    Mezei, Michelle M.
    Baker, Steven K.
    Breiner, Ari
    Dhawan, Priya
    Fiander, Amanda
    Fine, Nowell M.
    Hahn, Christopher
    Katzberg, Hans D.
    Khayambashi, Shahin
    Massie, Rami
    Matte, Genevieve
    Putko, Brendan
    Siddiqi, Zaeem
    Delgado, Diego
    Bril, Vera
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (01) : 7 - 18
  • [26] A new Thr49Pro transthyretin gene mutation associated with leptomeningeal amyloidosis
    Nakagawa, Kazuma
    Sheikh, Sarah I.
    Snuderl, Matija
    Frosch, Matthew P.
    Greenberg, Steven M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 272 (1-2) : 186 - 190
  • [27] Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature review
    Hong-Tao Chen
    You-Jun Tian
    Jue Zhang
    Bing-Rong Xiao
    Ke Yang
    Ya-Li Zhang
    Orphanet Journal of Rare Diseases, 20 (1)
  • [28] Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
    Carroll, Antonia
    Dyck, P. James
    de Carvalho, Mamede
    Kennerson, Marina
    Reilly, Mary M.
    Kiernan, Matthew C.
    Vucic, Steve
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, : 668 - 678
  • [29] A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK
    Carr, A. S.
    Pelayo-Negro, A. L.
    Evans, M. R. B.
    Laura, M.
    Blake, J.
    Stancanelli, C.
    Iodice, V.
    Wechalekar, A. D.
    Whelan, C. J.
    Gillmore, J. D.
    Hawkins, P. N.
    Reilly, M. M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (06) : 620 - 627
  • [30] Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies
    Warner, Alberta L.
    PHARMACOTHERAPY, 2021, 41 (12): : 1081 - 1091